---
title: "12:21 ETDEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281554443.md"
description: "Berger Montague PC has filed a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO) on behalf of investors who purchased American Depositary Shares from June 5, 2023, to December 26, 2025. Investors have until April 6, 2026, to seek lead plaintiff status. The lawsuit claims that Mereo misled investors about the success of its clinical trials, leading to a significant drop in share price after the trials failed to meet their primary endpoints."
datetime: "2026-04-02T16:22:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281554443.md)
  - [en](https://longbridge.com/en/news/281554443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281554443.md)
---

# 12:21 ETDEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against **Mereo BioPharma Group plc (NASDAQ: MREO)** ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from **June 5, 2023 through December 26, 2025** (the "Class Period").

**_Investor Deadline:_** _Investors who purchased Mereo securities during the Class Period may, no later than_ **_April 6, 2026_**_, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,_ **_CLICK HERE_**.

Mereo is a biopharmaceutical company focused on developing therapies for rare and serious diseases. The Company is headquartered in London, UK.

According to the lawsuit, throughout the Class Period, defendants issued overwhelmingly positive statements to investors concerning the ORBIT and COSMIC Phase 3 programs, clinical trials to test setrusumab as a treatment for Osteogenesis Imperfecta.

When, on December 29, 2025, Mereo disclosed that neither study achieved its primary endpoint of reducing the annualized clinical fracture rate, the price of its ADS dropped **_more than 87%_**, from a closing price of $2.31 per share on December 26, 2025 to a close of $0.29 per share on December 29, 2025.

**_If you are a Mereo investor and would like to learn more about this action,_** **_CLICK HERE_** **_or please contact Berger Montague: Andrew Abramowitz at_** **_\[email protected\]_** **_or (215) 875-3015, or Caitlin Adorni at_** **_\[email protected\]_** **_or (267) 764-4865._**

**About Berger Montague**

Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

**For more information or to discuss your rights, please contact:**

Andrew Abramowitz  
Berger Montague  
(215) 875-3015  
\[email protected\]

Caitlin Adorni  
Berger Montague  
(267) 764-4865  
\[email protected\]

SOURCE Berger Montague

### Related Stocks

- [MREO.US](https://longbridge.com/en/quote/MREO.US.md)

## Related News & Research

- [Balanced Risk-Reward Amid Clinical Uncertainty: Maintaining Hold on Mereo BioPharma](https://longbridge.com/en/news/279838373.md)
- [Mereo Biopharma Group Plc (MREO) Receives a Buy from Leerink Partners](https://longbridge.com/en/news/271216337.md)
- [Urban Edge (UE) Q1 2026 Earnings Transcript](https://longbridge.com/en/news/284615742.md)
- [A Look At Urban Edge Properties (UE) Valuation After Recent Share Price Momentum](https://longbridge.com/en/news/282822840.md)
- [Mereo BioPharma Group (NASDAQ:MREO) Releases Quarterly Earnings Results](https://longbridge.com/en/news/265408986.md)